Tejara Capital Ltd Invests $4.86 Million in ARS Pharmaceuticals, Inc. $SPRY

Tejara Capital Ltd purchased a new stake in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 607,039 shares of the company’s stock, valued at approximately $4,862,000. ARS Pharmaceuticals makes up approximately 2.0% of Tejara Capital Ltd’s portfolio, making the stock its 16th largest holding. Tejara Capital Ltd owned about 0.61% of ARS Pharmaceuticals at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the company. Rubric Capital Management LP increased its stake in ARS Pharmaceuticals by 29.0% during the first quarter. Rubric Capital Management LP now owns 8,000,000 shares of the company’s stock valued at $64,240,000 after purchasing an additional 1,800,000 shares during the last quarter. BlackRock Inc. bought a new stake in shares of ARS Pharmaceuticals during the 2nd quarter valued at about $42,544,000. Vanguard Group Inc. raised its stake in ARS Pharmaceuticals by 7.3% during the third quarter. Vanguard Group Inc. now owns 3,500,303 shares of the company’s stock worth $35,178,000 after acquiring an additional 237,630 shares during the period. State Street Corp lifted its holdings in ARS Pharmaceuticals by 11.3% in the fourth quarter. State Street Corp now owns 3,223,581 shares of the company’s stock worth $37,555,000 after acquiring an additional 328,325 shares during the last quarter. Finally, Millennium Management LLC bought a new position in ARS Pharmaceuticals in the fourth quarter worth about $36,912,000. 68.16% of the stock is currently owned by institutional investors.

ARS Pharmaceuticals Stock Performance

Shares of NASDAQ SPRY opened at $5.51 on Friday. The company has a current ratio of 3.48, a quick ratio of 3.28 and a debt-to-equity ratio of 13.72. The stock has a 50 day simple moving average of $7.32 and a 200-day simple moving average of $8.18. The company has a market cap of $547.97 million, a PE ratio of -2.53 and a beta of 0.98. ARS Pharmaceuticals, Inc. has a 12-month low of $4.91 and a 12-month high of $15.09.

ARS Pharmaceuticals (NASDAQ:SPRY) last posted its earnings results on Thursday, August 13th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.15). ARS Pharmaceuticals had a negative net margin of 184.24% and a negative return on equity of 256.67%. The business had revenue of $33.66 million during the quarter, compared to analyst estimates of $31.32 million. On average, equities research analysts forecast that ARS Pharmaceuticals, Inc. will post -1.9 EPS for the current year.

Analysts Set New Price Targets

SPRY has been the subject of a number of research reports. Leerink Partners decreased their target price on ARS Pharmaceuticals from $25.00 to $24.00 and set an “outperform” rating for the company in a research note on Thursday, June 25th. Wall Street Zen raised ARS Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Saturday, May 16th. Weiss Ratings lowered ARS Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday. Finally, Cantor Fitzgerald increased their target price on ARS Pharmaceuticals from $12.00 to $30.00 and gave the stock an “overweight” rating in a research report on Thursday, May 28th. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $28.20.

ARS Pharmaceuticals News Summary

Here are the key news stories impacting ARS Pharmaceuticals this week:

• Positive Sentiment: Wall Street analysts’ average price target implies approximately 297% potential upside from recent levels. Zacks also noted a favorable trend in earnings-estimate revisions, though it cautioned that price targets are an imperfect indicator. Can ARS Pharmaceuticals Climb to Reach Analysts’ Expectations?
• Neutral Sentiment: ARS Pharma’s second-quarter 2026 earnings call transcript was published, giving investors additional detail on the company’s financial results, commercial execution and outlook. The supplied report does not identify a specific new catalyst or guidance change. ARS Pharma Q2 2026 Earnings Call Transcript
• Negative Sentiment: Multiple law firms announced or promoted a securities class action against ARS Pharmaceuticals and certain officers. The lawsuit alleges that the company’s statements about a July 1, 2026 CVS Caremark formulary effective date failed to adequately warn that expanded coverage for neffy could be delayed until January 2027. The alleged disclosure issue reportedly preceded a single-day 23.9% share decline and a loss of approximately $2.52 per share for affected investors. The October 5, 2026 deadline to seek lead-plaintiff status adds continued legal and reputational overhang. These are allegations, not findings of wrongdoing. SPRY Investor Alert and Securities Class Action Notice

Insider Transactions at ARS Pharmaceuticals

In related news, insider Eric Karas sold 25,000 shares of the firm’s stock in a transaction that occurred on Friday, June 12th. The shares were sold at an average price of $10.00, for a total transaction of $250,000.00. Following the transaction, the insider owned 12,176 shares in the company, valued at $121,760. This trade represents a 67.25% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Alexander A. Fitzpatrick sold 3,355 shares of the business’s stock in a transaction that occurred on Friday, June 12th. The stock was sold at an average price of $10.00, for a total value of $33,550.00. Following the sale, the insider directly owned 90,910 shares in the company, valued at approximately $909,100. The trade was a 3.56% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 33.80% of the stock is owned by insiders.

ARS Pharmaceuticals Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc was founded in 2015 and is headquartered in San Diego, California.